Cyclerion Therapeutics, Inc. CYCN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
53/100
Moderate

Ranked against 712 peers in Biotechnology

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment … Full CYCN analysis →

Key strengths

  • Scale Supporting Profitability Profitability at scale is strong (score 0.81), demonstrating competitive advantages.
  • Operating Leverage in Effect Operating leverage is evident (score 0.85), with margins expanding over time.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.40), raising refinancing risk.
  • Volatile Margins Suggest Cyclicality Margin volatility is high (stability score 0.35), suggesting cyclical exposure or competitive pressure.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
38
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CYCN ranks in Biotechnology

Cyclerion Therapeutics, Inc. ranks #200 of 713 scored companies in Biotechnology by moat score — the top 28%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
196 HOOKIPA Pharma Inc. HOOK 53/100 Moderate
197 Maravai LifeSciences Holdings, MRVI 53/100 Moderate
198 Zentalis Pharmaceuticals, Inc. ZNTL 53/100 Moderate
199 Arcus Biosciences, Inc. RCUS 53/100 Moderate
200 Cyclerion Therapeutics, Inc. CYCN 53/100 Moderate
201 Lexicon Pharmaceuticals, Inc. LXRX 53/100 Moderate
202 Cassava Sciences, Inc. SAVA 53/100 Moderate
203 Curis, Inc. CRIS 53/100 Moderate
204 Evogene Ltd. EVGN 53/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How CYCN scores on the Corporate Default defenses

Pricing Power

Score 38 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 54 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 66 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 36 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 49 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 82 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CYCN's moat

What is Cyclerion Therapeutics, Inc.'s moat score?

Cyclerion Therapeutics, Inc. (CYCN) scores 53 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #200 of 713 scored companies in Biotechnology, the top 28%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (82/100) and its weakest is Capital Efficiency (36/100).

How does Cyclerion Therapeutics, Inc. compare with other Biotechnology companies?

Cyclerion Therapeutics, Inc. ranks #200 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Arcus Biosciences, Inc. (RCUS) at 53 just above it and Lexicon Pharmaceuticals, Inc. (LXRX) at 53 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Cyclerion Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Cyclerion Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and CYCN scores: Pricing Power (38), Cost Advantage (54), Customer Stickiness (66), Capital Efficiency (36), Resilience (49), Scale & Market Position (82). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000